Cargando…

PTEN Depletion Decreases Disease Severity and Modestly Prolongs Survival in a Mouse Model of Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is the second most common genetic cause of death in childhood. However, no effective treatment is available to halt disease progression. SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene. We previously reported that PTEN depletion leads to an increas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Little, Daniel, Valori, Chiara F, Mutsaers, Chantal A, Bennett, Ellen J, Wyles, Matthew, Sharrack, Basil, Shaw, Pamela J, Gillingwater, Thomas H, Azzouz, Mimoun, Ning, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445616/ https://www.ncbi.nlm.nih.gov/pubmed/25369768 http://dx.doi.org/10.1038/mt.2014.209

Ejemplares similares

Viral Delivery of Antioxidant Genes as a Therapeutic Strategy in Experimental Models of Amyotrophic Lateral Sclerosis
por: Nanou, Aikaterini, et al.
Publicado: (2013)

Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy
por: Mutsaers, Chantal A, et al.
Publicado: (2013)

Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy
por: Powis, Rachael A., et al.
Publicado: (2016)

Morphological Characteristics of Motor Neurons Do Not Determine Their Relative Susceptibility to Degeneration in a Mouse Model of Severe Spinal Muscular Atrophy
por: Thomson, Sophie R., et al.
Publicado: (2012)

Plastin 3 Promotes Motor Neuron Axonal Growth and Extends Survival in a Mouse Model of Spinal Muscular Atrophy
por: Alrafiah, Aziza, et al.
Publicado: (2018)

Revisiting the role of mitochondria in spinal muscular atrophy
por: James, Rachel, et al.
Publicado: (2021)

Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis
por: Kirby, Janine, et al.
Publicado: (2011)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
por: Sleigh, James N., et al.
Publicado: (2011)

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy
por: Shorrock, Hannah K., et al.
Publicado: (2018)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy
por: Motyl, Anna A.L., et al.
Publicado: (2022)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)

Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
por: Chaytow, Helena, et al.
Publicado: (2021)

Early Detection of Motor Dysfunction in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis (ALS) Using Home Cage Running Wheels
por: Bennett, Ellen J., et al.
Publicado: (2014)

C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten
por: Stopford, Matthew J., et al.
Publicado: (2017)

Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy
por: Yeo, Crystal Jing Jing, et al.
Publicado: (2020)

Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment
por: Degner, Kenna R., et al.
Publicado: (2021)

A Case of Muscular Atrophy Due to Lead
por: Shaw, J. E.
Publicado: (1901)

A call to introduce newborn screening for spinal muscular atrophy (SMA) in Scotland
por: Gillingwater, Thomas H., et al.
Publicado: (2022)

A Case of Neuritic Muscular Atrophy ("Peroneal" Type)
por: Shaw, J. E.
Publicado: (1899)

PTEN regulates AMPA receptor-mediated cell viability in iPS-derived motor neurons
por: Yang, D-J, et al.
Publicado: (2014)

A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN
por: Rademacher, Sebastian, et al.
Publicado: (2020)

Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy
por: Motyl, Anna A L, et al.
Publicado: (2020)

Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease
por: Boczonadi, Veronika, et al.
Publicado: (2018)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omer, M. A.
Publicado: (1949)

Muscular Atrophy and Sclerodermia
por: Nixon, J. A.
Publicado: (1903)

Progressive Muscular Atrophy
Publicado: (1874)

Muscular Atrophy and Sclerodermia
Publicado: (1904)

Acute Muscular Atrophy
por: Haddon, John
Publicado: (1870)

Case of Muscular Atrophy
por: Kersey, V.
Publicado: (1871)

Case of Marked Muscular Atrophy of Hands and Fore-Arms—Progressive Muscular Atrophy(?)
por: Ness, R. Barclay
Publicado: (1895)

Neurochondrin interacts with the SMN protein suggesting a novel mechanism for spinal muscular atrophy pathology
por: Thompson, Luke W., et al.
Publicado: (2018)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Correction: Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy–like disease
por: Boczonadi, V., et al.
Publicado: (2019)

Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy
por: Opris¸oreanu, Ana-Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_79a7r2jfahllt3lrs374809j1a